Acute manganese administration alters dopamine transporter levels in the non-human primate striatum.

We used positron emission tomography (PET) to measure non-invasively the effect of acute systemic administration to manganese sulfate (MnSO4) on dopamine transporter (DAT) levels in the living non-human primate brain. Baboons received [11C]-WIN 35,428 PET scans to measure DAT levels before and after acute MnSO4 administration. In one animal, we observed a 46% increase in DAT binding potential (BP), a measure of DAT binding site availability, 1 week after Mn administration. DAT levels returned to baseline values at 4 months and remained constant at 10 months after treatment. A subsequent single MnSO4 injection to the same animal also resulted in a 57% increase in DAT-BP, 2 days after administration. In a second animal, a 76% increase in DAT-BP relative to baseline was observed at 3 days after Mn injection. In this animal, the DAT-BP returned to baseline levels after 1 month. Using in vitro receptor binding assays, we found that Mn inhibits [3H]-WIN 35,428 binding to rat striatal DAT with an inhibitory constant (Ki) of 2.0+/-0.3mM (n=4). Saturation isotherms and Scatchard analysis of [3H]-WIN 35,428 binding to rat striatal DAT showed a significant decrease (30%, p<0.001) in the maximal number of binding sites (Bmax) in the presence of 2mM MnSO4. No significant effect of Mn was found on binding affinity (Kd). We also found that Mn inhibits [3H]-dopamine uptake with an IC50 of 11.4+/-1.5mM (n=4). Kinetic studies and Lineweaver-Burk analysis showed a significant decrease (40%, p<0.001) in the maximal velocity of uptake (Vmax) with 5mM MnSO4. No significant effect of Mn was found on Michaelis-Menten constant (Km). These in vitro findings suggest that the increase in DAT levels in vivo following acute Mn administration may be a compensatory response to its inhibitory action on DAT. These findings provide helpful insights on potential mechanisms of Mn-induced neurotoxicity and indicate that the DAT in the striatum is a target for Mn in the brain.

[1]  D. Wong,et al.  In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428 , 1993, Synapse.

[2]  C. Angle,et al.  Manganese encephalopathy: utility of early magnetic resonance imaging. , 1993, British journal of industrial medicine.

[3]  D. Jennings,et al.  Prevalence of parkinsonism and relationship to exposure in a large sample of Alabama welders , 2005, Neurology.

[4]  T. Yen,et al.  Dopamine Transporter Binding in Wilson's Disease , 2003, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[5]  A. Levey,et al.  Dopamine transporters and neuronal injury. , 1999, Trends in pharmacological sciences.

[6]  David C. Dorman,et al.  Manganese Dosimetry: Species Differences and Implications for Neurotoxicity , 2005, Critical reviews in toxicology.

[7]  B. Långström,et al.  Manganese induced brain lesions inMacaca fascicularis as revealed by positron emission tomography and magnetic resonance imaging , 2005, Archives of Toxicology.

[8]  M. Canesi,et al.  Welding-related parkinsonism: Clinical features, treatment, and pathophysiology , 2001, Neurology.

[9]  Håkan Eriksson,et al.  Effect of long-term administration of manganese on biogenic amine levels in discrete striatal regions of rat brain , 1987, Archives of Toxicology.

[10]  T. Yen,et al.  Dopamine transporter binding in chronic manganese intoxication , 2003, Journal of Neurology.

[11]  Alan A. Wilson,et al.  Synthesis of a radiotracer for studying dopamine uptake sites in vivo using PET: 2β‐carbomethoxy‐3β‐(4‐fluorophenyl)‐[N‐11C‐methyl]tropane ([11C]CFT or [11C]WIN‐35,428) , 1993 .

[12]  E. Costa,et al.  Selective depletion of caudate nucleus dopamine and serotonin during chronic manganese dioxide administration to squirrel monkeys , 1969, Experientia.

[13]  E. Montgomery,et al.  Central nervous system toxicity of manganese. II: Cocaine or reserpine inhibit manganese concentration in the rat brain. , 1999, Neurotoxicology.

[14]  N. Zahniser,et al.  Rapid regulation of dopamine transporter function by substrates, blockers and presynaptic receptor ligands. , 2003, European journal of pharmacology.

[15]  H. Watanabe,et al.  Chronic manganese poisoning: A neuropathological study with determination of manganese distribution in the brain , 2004, Acta Neuropathologica.

[16]  M. Reith,et al.  [3H]WIN 35,428 binding to the dopamine uptake carrier. I. Effect of tonicity and buffer composition , 1994, Journal of Neuroscience Methods.

[17]  B Weiss,et al.  Persistent effects of manganese on effortful responding and their relationship to manganese accumulation in the primate globus pallidus. , 1992, Toxicology and applied pharmacology.

[18]  C. Yoo,et al.  Dopamine transporter density is decreased in parkinsonian patients with a history of manganese exposure: What does it mean? , 2002, Movement disorders : official journal of the Movement Disorder Society.

[19]  G D Pfeifer,et al.  Environmental effects and exposures to manganese from use of methylcyclopentadienyl manganese tricarbonyl (MMT) in gasoline. , 1999, Neurotoxicology.

[20]  Bernard Weiss,et al.  Visualizing manganese in the primate basal ganglia with magnetic resonance imaging , 1989, Experimental Neurology.

[21]  D B Calne,et al.  Manganese neurotoxicity: a review of clinical features, imaging and pathology. , 1999, Neurotoxicology.

[22]  S. Aquilonius,et al.  Receptor alterations in manganese intoxicated monkeys , 2005, Archives of Toxicology.

[23]  E. Richfield,et al.  Increased synaptosomal dopamine content and brain concentration of paraquat produced by selective dithiocarbamates , 2003, Journal of neurochemistry.

[24]  S. Amara,et al.  Dynamic regulation of the dopamine transporter. , 2003, European journal of pharmacology.

[25]  C. W. Olanow,et al.  Manganese intoxication in the rhesus monkey , 1996, Neurology.